TransMedics shares dropped 9% after Q3 results showed margin pressure and a sequential slowdown despite strong yearly growth. The firm reaffirmed 2025 guidance and detailed plans for a 22-aircraft US fleet and new Italy hub. The organ transplant technology company's Q3 revenue was $143.8 million, an increase of 32% over the same period a year ago.